Menu

Biology, Genetics & Bone Healing MCQs

Practice Set 89 of 212

This practice set contains high-yield board review questions covering key concepts in Biology, Genetics & Bone Healing. Each clinical scenario is designed to test your diagnostic and management skills relevant to this subspecialty.

Question 1761

Topic: Biology, Genetics & Bone Healing

A 45-year-old man undergoes closed reduction and intramedullary nailing for a closed, transverse midshaft tibial fracture. Which of the following accurately describes the predominant mechanism of bone healing expected in this scenario?

. Primary bone healing via Haversian remodeling and cutting cones
. Intramembranous ossification with direct woven bone formation without a cartilage intermediate
. Secondary bone healing primarily through endochondral ossification
. Creeping substitution characterized by osteoclastic resorption and osteoblastic deposition
. Distraction osteogenesis relying on continuous tension forces

Correct Answer & Explanation

. Secondary bone healing primarily through endochondral ossification

Explanation

Intramedullary nailing of a diaphyseal long bone fracture provides relative stability (as opposed to absolute stability achieved with rigid plate fixation). Relative stability promotes secondary bone healing, which involves callus formation. This process predominantly occurs via endochondral ossification, where a cartilaginous intermediate is formed and subsequently replaced by bone. Primary bone healing (via cutting cones) occurs only under conditions of absolute stability and anatomic reduction without gap formation.

Question 1762

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with worsening right knee pain. Radiographs reveal a large, eccentric, purely lytic, epiphyseal-metaphyseal lesion in the proximal tibia extending to the subchondral bone. Histology shows numerous multinucleated giant cells in a background of mononuclear spindle cells. The patient is deemed an unresectable surgical candidate and denosumab therapy is initiated. What is the precise mechanism of action of this medication?

. Inhibits VEGF to decrease tumor angiogenesis
. Inhibits the tyrosine kinase domain of c-kit
. Cross-links DNA, leading to cellular apoptosis
. Binds to RANKL, preventing osteoclast and giant cell activation
. Antagonizes estrogen receptors on the neoplastic stromal cells

Correct Answer & Explanation

. Binds to RANKL, preventing osteoclast and giant cell activation

Explanation

Giant cell tumors of bone consist of neoplastic mononuclear stromal cells that express high levels of RANKL. This recruits and activates reactive multinucleated giant cells (osteoclast-like cells) responsible for extensive bone resorption. Denosumab is a fully human monoclonal antibody that binds directly to RANKL, interrupting this pathway, leading to a dramatic reduction in giant cells, tumor necrosis, and subsequent ossification.

Question 1763

Topic: Biology, Genetics & Bone Healing

A 65-year-old woman with severe osteoporosis is started on denosumab therapy. This medication primarily exerts its mechanism of action by directly inhibiting which of the following cellular interactions?

. Binding of RANKL to RANK on osteoblast precursors
. Binding of RANKL to RANK on osteoclast precursors
. Binding of OPG to RANKL
. Binding of PTH to osteoblasts
. Secretion of cathepsin K by mature osteoclasts

Correct Answer & Explanation

. Binding of RANKL to RANK on osteoclast precursors

Explanation

Denosumab is a human monoclonal antibody that specifically targets and binds to Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). By binding to RANKL, denosumab prevents it from interacting with RANK on the surface of osteoclasts and osteoclast precursors. This inhibits osteoclastogenesis, osteoclast function, and survival, ultimately reducing bone resorption.

Question 1764

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with worsening knee pain. Radiographs display an eccentric, lytic epiphyseal-metaphyseal lesion of the distal femur extending to the subchondral bone. A biopsy demonstrates numerous multinucleated giant cells uniformly distributed in a background of mononuclear stromal cells. Which of the following statements is true regarding the cellular biology and treatment of this lesion?

. The giant cells are the true neoplastic component of the tumor
. The neoplastic mononuclear cells express high levels of RANK
. Treatment with denosumab targets the multinucleated giant cells directly
. The neoplastic mononuclear cells express high levels of RANKL
. The tumor typically exhibits a t(11;22) translocation

Correct Answer & Explanation

. The neoplastic mononuclear cells express high levels of RANKL

Explanation

In Giant Cell Tumor (GCT) of bone, the true neoplastic cells are the spindle-shaped mononuclear stromal cells. These neoplastic cells express high levels of RANKL, which recruits and stimulates the formation of reactive, non-neoplastic multinucleated giant cells (which express the RANK receptor). Denosumab targets the RANKL produced by the neoplastic mononuclear cells, thereby indirectly halting the action of the osteoclast-like giant cells.

Question 1765

Topic: Biology, Genetics & Bone Healing

A 35-year-old man undergoes open reduction and internal fixation of a diaphyseal radius fracture. The surgeon utilizes compression plating to achieve absolute stability. Assuming standard biological conditions, which of the following mechanisms best describes the primary mode of fracture healing expected?

. Endochondral ossification
. Intramembranous ossification with robust callus formation
. Haversian remodeling via cutting cones across the fracture site
. Differentiation of mesenchymal stem cells into chondrocytes
. Intermembranous ossification followed by enchondral ossification

Correct Answer & Explanation

. Haversian remodeling via cutting cones across the fracture site

Explanation

Fixation that achieves absolute stability (strain < 2%) suppresses callus formation and leads to primary (direct) bone healing. Primary bone healing occurs via direct Haversian remodeling, where osteoclasts create cutting cones that cross the fracture line, followed immediately by osteoblasts laying down new osteons. Secondary bone healing (which involves callus formation via endochondral and intramembranous ossification) occurs with relative stability constructs (e.g., intramedullary nails, external fixators).

Question 1766

Topic: Biology, Genetics & Bone Healing

A 28-year-old female presents with progressive knee pain. Radiographs reveal an eccentric, purely lytic epiphyseal lesion extending to the subchondral bone of the distal femur. Histological analysis confirms the presence of uniform mononuclear cells mixed with numerous multinucleated giant cells. For unresectable or recurrent disease, systemic therapy can be utilized. Which of the following pathways is the primary target for the medication used in this clinical scenario?

. Vascular endothelial growth factor (VEGF) inhibition
. Receptor activator of nuclear factor kappa-B ligand (RANKL) inhibition
. Mammalian target of rapamycin (mTOR) inhibition
. Tyrosine kinase inhibition
. Tumor necrosis factor-alpha (TNF-a) inhibition

Correct Answer & Explanation

. Receptor activator of nuclear factor kappa-B ligand (RANKL) inhibition

Explanation

The patient has a Giant Cell Tumor of Bone (GCTB), characterized by an eccentric, lytic epiphyseal lesion in a skeletally mature individual. The neoplastic mononuclear cells in GCTB express high levels of RANKL, which recruits and activates the reactive multinucleated osteoclast-like giant cells that cause the massive bone destruction. Denosumab is a monoclonal antibody that inhibits RANKL and is FDA-approved for the treatment of GCTB that is unresectable or where resection would result in severe morbidity.

Question 1767

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with severe knee pain and a lytic lesion in the proximal tibia extending right to the subchondral bone. Biopsy confirms a giant cell tumor of bone (GCTB). Due to the extensive size and joint proximity precluding immediate joint-salvage surgery, neoadjuvant medical therapy is planned. Which of the following accurately describes the mechanism of the most appropriate pharmacological agent?

. Inhibition of vascular endothelial growth factor (VEGF) receptors to decrease tumor angiogenesis
. Direct induction of apoptosis in the reactive multinucleated giant cells via bisphosphonate-like action
. Monoclonal antibody binding to RANKL, preventing activation of RANK on osteoclast precursors
. Inhibition of matrix metalloproteinases (MMPs) preventing subchondral cartilage degradation
. Binding to the intracellular domain of tyrosine kinase, inhibiting downstream neoplastic proliferation

Correct Answer & Explanation

. Monoclonal antibody binding to RANKL, preventing activation of RANK on osteoclast precursors

Explanation

Denosumab is highly effective as neoadjuvant therapy for large, complex Giant Cell Tumors of Bone (GCTB) to induce ossification, solidify the tumor margins, and reduce surgical morbidity. It is a fully human monoclonal antibody that binds to RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). The neoplastic mononuclear stromal cells in GCTB secrete large amounts of RANKL, which recruits and activates the reactive multinucleated giant cells (osteoclast-like cells) expressing RANK. By neutralizing RANKL, denosumab prevents the differentiation and bone-resorbing function of these giant cells.

Question 1768

Topic: Biology, Genetics & Bone Healing

A 4-year-old girl is evaluated for recurrent fractures following minimal trauma. Clinical examination reveals blue sclerae and evidence of dentinogenesis imperfecta. Genetic testing confirms a mutation in COL1A1. Which of the following mechanisms best describes the action of the medical therapy most commonly used to decrease fracture burden in this patient?

. Inhibition of osteoclast-mediated bone resorption
. Stimulation of osteoblast differentiation
. Direct stimulation of type I collagen synthesis
. Antagonism of the RANKL pathway
. Enhancement of intestinal calcium absorption

Correct Answer & Explanation

. Inhibition of osteoclast-mediated bone resorption

Explanation

The patient has Osteogenesis Imperfecta (OI), characterized by defective type I collagen. The mainstay of medical management to reduce fracture burden is the use of bisphosphonates (e.g., pamidronate or zoledronic acid). Bisphosphonates act by inducing osteoclast apoptosis and inhibiting osteoclast-mediated bone resorption, thereby increasing cortical thickness and trabecular bone density, though they do not correct the underlying collagen defect.

Question 1769

Topic: Biology, Genetics & Bone Healing
A 5-year-old girl with Osteogenesis Imperfecta (Type III) has a history of recurrent long bone fractures and progressive bowing deformities. She is receiving cyclical intravenous pamidronate therapy. This pharmacological agent decreases the incidence of fractures primarily through which of the following cellular mechanisms?
. Stimulating mesenchymal stem cell differentiation into osteoblasts
. Increasing the cross-linking of Type I collagen molecules
. Inhibiting farnesyl pyrophosphate synthase, leading to osteoclast apoptosis
. Acting as a selective estrogen receptor modulator (SERM) on bone tissue
. Directly binding to RANKL to prevent osteoclastogenesis

Correct Answer & Explanation

. Inhibiting farnesyl pyrophosphate synthase, leading to osteoclast apoptosis

Explanation

Pamidronate is a nitrogen-containing bisphosphonate widely used in the medical management of moderate to severe Osteogenesis Imperfecta. These agents work by being internalized by osteoclasts during bone resorption. Inside the osteoclast, they inhibit the enzyme farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway. This disruption prevents the prenylation of small GTPase proteins essential for osteoclast function and survival, ultimately leading to osteoclast apoptosis and decreased bone turnover. They do not correct the underlying Type I collagen defect.

Question 1770

Topic: Biology, Genetics & Bone Healing

A 4-year-old child with a known history of recurrent fractures and blue sclerae is being treated with intravenous bisphosphonate therapy (pamidronate).

Radiographs of the long bones demonstrate multiple dense horizontal bands ('zebra lines') in the metaphyses. What is the primary mechanism by which this medication produces these radiographic findings?

. Stimulation of osteoblast differentiation and proliferation
. Inhibition of osteoclast-mediated bone resorption
. Direct inhibition of type 1 collagen synthesis
. Upregulation of the runx2 gene expression
. Inhibition of tissue non-specific alkaline phosphatase activity

Correct Answer & Explanation

. Inhibition of osteoclast-mediated bone resorption

Explanation

The patient has Osteogenesis Imperfecta (OI). Bisphosphonates, such as pamidronate, act by inhibiting osteoclast activity and inducing osteoclast apoptosis, thereby decreasing bone resorption. When administered cyclically, the periods of osteoclast inhibition leave behind bands of unresorbed calcified cartilage in the growing metaphyses, appearing as parallel radiodense lines known as 'zebra lines'.

Question 1771

Topic: Biology, Genetics & Bone Healing

A 3-year-old boy presents with a history of 4 low-energy fractures. Physical examination reveals blue sclerae, joint hyperlaxity, and mild dentinogenesis imperfecta. Genetic testing confirms a mutation in the COL1A1 gene. The patient is initiated on intravenous pamidronate therapy. Which of the following best describes the expected radiographic changes following treatment and the specific cellular mechanism of this medication?

. Dense metaphyseal bands due to inhibition of osteoclast-mediated bone resorption
. Widened physes due to direct stimulation of osteoblast proliferation
. Cortical thinning due to down-regulation of type 1 collagen synthesis
. Sclerotic diaphyseal lesions due to inhibition of matrix metalloproteinases
. Periosteal reaction due to a secondary inflammatory cascade

Correct Answer & Explanation

. Dense metaphyseal bands due to inhibition of osteoclast-mediated bone resorption

Explanation

The patient has Osteogenesis Imperfecta (OI). Bisphosphonates, such as pamidronate, are the medical treatment of choice for moderate to severe OI. They are antiresorptive agents that act by inhibiting osteoclast activity and inducing osteoclast apoptosis. Because the normal resorption of calcified cartilage at the physis is inhibited during cyclical IV bisphosphonate therapy, horizontal sclerotic lines form parallel to the growth plate. These are known as 'zebra lines' or dense metaphyseal bands. Bisphosphonates do not directly stimulate osteoblasts or down-regulate collagen synthesis.

Question 1772

Topic: Biology, Genetics & Bone Healing

A 5-year-old boy with recurrent fractures, blue sclerae, and dentinogenesis imperfecta is initiated on intravenous pamidronate therapy. Which of the following best describes the primary mechanism of action of this medication in this patient?

. Stimulation of osteoblast differentiation and proliferation
. Inhibition of osteoclast-mediated bone resorption
. Enhancement of Type 1 collagen cross-linking
. Upregulation of runx2 expression in osteoprogenitor cells
. Inhibition of sclerostin leading to increased bone formation

Correct Answer & Explanation

. Inhibition of osteoclast-mediated bone resorption

Explanation

Bisphosphonates like pamidronate act primarily by inducing apoptosis in osteoclasts, thereby inhibiting osteoclast-mediated bone resorption. This increases overall bone mineral density and decreases fracture burden in patients with osteogenesis imperfecta.

Question 1773

Topic: Biology, Genetics & Bone Healing

A 4-year-old boy presents with profound lower extremity bowing. Laboratory testing reveals hypophosphatemia, elevated alkaline phosphatase, and normal serum calcium. Genetic testing confirms a mutation in the PHEX gene. The pathophysiology of his bone disease is primarily driven by an excess of which of the following?

. Parathyroid hormone (PTH)
. 1,25-dihydroxyvitamin D
. Fibroblast growth factor 23 (FGF23)
. Alkaline phosphatase
. Calcitonin

Correct Answer & Explanation

. Fibroblast growth factor 23 (FGF23)

Explanation

The patient has X-linked hypophosphatemic (XLH) rickets due to a PHEX mutation. This mutation leads to an overproduction of FGF23, which impairs renal phosphate reabsorption, causing hypophosphatemia and rickets.

Question 1774

Topic: Biology, Genetics & Bone Healing

A 4-year-old boy with multiple recurrent fractures, blue sclerae, and dentinogenesis imperfecta is diagnosed with Osteogenesis Imperfecta (OI) type I. He is started on intravenous pamidronate. What is the primary mechanism of action of this medication in the treatment of OI?

. Stimulation of osteoblast proliferation and differentiation
. Enhancement of intestinal calcium absorption
. Promotion of enzymatic cross-linking of type I collagen
. Inhibition of osteoclast-mediated bone resorption
. Promotion of transforming growth factor-beta release

Correct Answer & Explanation

. Inhibition of osteoclast-mediated bone resorption

Explanation

Bisphosphonates, such as pamidronate, are the mainstay of medical therapy for moderate to severe Osteogenesis Imperfecta. They function by inhibiting osteoclast activity and inducing osteoclast apoptosis, thereby decreasing bone turnover and increasing bone mineral density.

Question 1775

Topic: Biology, Genetics & Bone Healing
A 6-year-old boy with Osteogenesis Imperfecta Type III is undergoing treatment with intravenous pamidronate. By what mechanism does this medication reduce fracture incidence?
. Stimulating osteoblast bone formation
. Inducing apoptosis of osteoclasts
. Increasing collagen type I synthesis
. Enhancing calcium absorption in the gut
. Promoting endochondral ossification

Correct Answer & Explanation

. Inducing apoptosis of osteoclasts

Explanation

Bisphosphonates like pamidronate accumulate in the bone matrix and are ingested by osteoclasts during resorption, inducing osteoclast apoptosis. This reduces bone turnover and increases bone density in patients with Osteogenesis Imperfecta.

Question 1776

Topic: Biology, Genetics & Bone Healing

Intravenous bisphosphonates are a mainstay of medical management for children with moderate to severe Osteogenesis Imperfecta (OI). What is the primary mechanism of action of this medication class in altering the disease course?

. Stimulation of osteoblast proliferation and differentiation
. Inhibition of osteoclast-mediated bone resorption
. Direct augmentation of type I collagen cross-linking
. Prevention of primary osteoid mineralization
. Upregulation of endochondral ossification at the physis

Correct Answer & Explanation

. Inhibition of osteoclast-mediated bone resorption

Explanation

Bisphosphonates bind firmly to hydroxyapatite crystals in bone and potently inhibit osteoclast-mediated bone resorption. In OI, this allows bone formation to outpace resorption, leading to increased cortical thickness, greater bone mineral density, and decreased fracture rates.

Question 1777

Topic: Biology, Genetics & Bone Healing
A 32-year-old man on chronic systemic corticosteroids presents with right hip pain. MRI reveals a crescent-shaped subchondral fracture in the superior femoral head, but plain radiographs only show patchy sclerosis without gross collapse. According to the modified Ficat classification, what is the stage and most appropriate joint-preserving recommendation?
. Stage I; Core decompression
. Stage II; Free vascularized fibular graft
. Stage III; Bisphosphonate therapy
. Stage III; Core decompression is no longer indicated
. Stage IV; Hip resurfacing

Correct Answer & Explanation

. Stage III; Core decompression is no longer indicated

Explanation

A subchondral fracture (crescent sign) indicates structural failure and defines Ficat Stage III osteonecrosis. Core decompression is typically indicated for pre-collapse (Stage I and II) disease and is generally ineffective once a subchondral fracture has occurred.

Question 1778

Topic: Biology, Genetics & Bone Healing

Which of the following Magnetic Resonance Imaging (MRI) findings is considered highly specific for the early diagnosis of avascular necrosis (osteonecrosis) of the femoral head prior to the appearance of radiographic changes?

. Diffuse bone marrow edema extending into the intertrochanteric region
. A solitary large subchondral cyst
. The 'double-line' sign on T2-weighted images
. Thickening and hyperintensity of the ligamentum teres
. Significant intra-articular joint effusion with synovial hypertrophy

Correct Answer & Explanation

. The 'double-line' sign on T2-weighted images

Explanation

The 'double-line' sign seen on T2-weighted MRI is considered highly specific for osteonecrosis (AVN) of the femoral head. It represents the reactive interface between necrotic and viable bone. The inner hyperintense (bright) line represents highly vascularized granulation tissue, while the outer hypointense (dark) line corresponds to sclerotic bone. Diffuse bone marrow edema without a focal lesion is more characteristic of transient osteoporosis of the hip.

Question 1779

Topic: Biology, Genetics & Bone Healing

Which of the following cell types and cytokines are most directly responsible for the capsular fibrosis seen in the proliferative stage of adhesive capsulitis?

. Chondrocytes and IL-1
. Fibroblasts and TGF-beta
. Osteoblasts and BMP-2
. Macrophages and TNF-alpha
. Synoviocytes and IL-6

Correct Answer & Explanation

. Fibroblasts and TGF-beta

Explanation

The pathophysiology of adhesive capsulitis is characterized by synovial inflammation followed by capsular fibrosis. Fibroblasts and myofibroblasts proliferate in response to cytokines like TGF-beta, PDGF, and basic FGF, leading to a thickened, contracted capsule.

Question 1780

Topic: Biology, Genetics & Bone Healing

A 65-year-old woman is evaluated for osteoporosis. She is started on denosumab. What is the precise mechanism of action of this medication?

. Monoclonal antibody that binds to RANKL, preventing its interaction with RANK
. Bisphosphonate that inhibits farnesyl pyrophosphate synthase
. Recombinant parathyroid hormone analog that stimulates osteoblast activity
. Selective estrogen receptor modulator that acts as an agonist in bone
. Sclerostin inhibitor that increases Wnt signaling

Correct Answer & Explanation

. Monoclonal antibody that binds to RANKL, preventing its interaction with RANK

Explanation

Denosumab is a fully human monoclonal antibody that specifically binds to the receptor activator of nuclear factor kappa-B ligand (RANKL). By binding to RANKL, denosumab prevents the interaction of RANKL with RANK, a receptor located on the surface of osteoclasts and their precursors. This inhibition prevents the formation, function, and survival of osteoclasts, leading to decreased bone resorption and increased bone mass.

Test Yourself

Switch to an interactive, timed exam simulation to truly master this topic.

On this Page